| Abstract | Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation. |
| Authors | Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen
(Affiliation: Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon, France.)
|
| Journal | Clinical neurology and neurosurgery
(Clin Neurol Neurosurg)
Vol. 107
Issue 4
Pg. 269-81
(Jun 2005)
ISSN: 0303-8467 Netherlands |
| PMID | 15885384
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Antiparkinson Agents
- Nerve Growth Factors
- Neuroprotective Agents
|
| Topics |
- Animals
- Antiparkinson Agents
(therapeutic use)
- Deep Brain Stimulation
- Dyskinesias
(etiology, therapy)
- Globus Pallidus
(surgery)
- Humans
- Nerve Growth Factors
(therapeutic use)
- Neurons
(transplantation)
- Neuroprotective Agents
(therapeutic use)
- Parkinson Disease
(complications)
- Thalamus
(surgery)
|
